Even simpler is this:
This is a dog of a stock with a bad history, and that is a fact. Investors have long memories.
Another fact: ReCell is already approved in many countries around the world.
So why isn't AVH "flying high" already?
FDA approval is not going to be the silver bullet some think it may be. Otherwise, why isn't AVH making a motza already?
This question cannot be ignored, and the broader hasn't, and AVH is priced accordingly.
No amount of spin and excuses will change this situation.
next?, page-59
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
